Latest revenue
$522.0K
as of 2024-09-30
Latest net income
$-4.7M
as of 2024-09-30
Net margin
-905.7%
as of 2024-09-30
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $7.7M
- Enterprise value
- $7.7M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $0.18
- 52-wk low
- $0.02
- Beta
- —
- Shares out
- 331.2M
5-year trend
dashed bar = fiscal Q4 derived from 10-K annual − Q1 − Q2 − Q3 (SEC requires only three 10-Qs per year).
What this company does
Item 1. Business. Introductory Note In this Annual Report, we use the terms “KidneyIntelX”, “KidneyIntelX Technology”, “KidneyIntelX Technology Platform” and “kidneyintelX.dkd.” When we refer to KidneyIntelX, we are referring to our diagnostic platform and any products developed based on this platform including our KidneyIntelX laboratory developed test offered as a testing service across the United States from our CLIA certified laboratories. When we refer to kidneyintelX.dkd, we are referring to the specific testing service from our KidneyIntelX technology platform or KidneyIntelX technology that has received De Novo marketing authorization from the U.S. Food and Drug Administration…
AI summary unavailable — showing raw filing excerpt
Generated from RENXF's filing dated 2024-09-30
Key risks
Item 1A. Risk Factors. Our business faces significant risks. You should carefully consider all of the information set forth in this annual report and in our other filings with the SEC, including the following risk factors which we face and which are faced by our industry. Our business, financial condition or results of operations could be materially adversely affected by any of these risks. This annual report also contains forward-looking statements that involve risks and uncertainties. Our results could materially differ from those anticipated in these forward-looking statements, as a result of certain factors including the risks described below and elsewhere in this annual report and our…
AI summary unavailable — showing raw filing excerpt
Generated from RENXF's filing dated 2024-09-30
Profitability
Gross margin
6.8%
67.8%Operating margin
-1293.5%
4.3%Net margin
-1461.6%
9.1%Return on equity
426.0%
165.1%Return on assets
-419.7%
181.8%Leverage
Debt / equity
-2.02×
159.3%Long-term debt / equity
-0.55×
151.3%Debt / assets
198.5%
157.0%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q3 2024 2024-09-30 | $522.0K | +13.7% | $-4.7M | +53.4% | -905.7% |
Q2 2024 2024-06-30 | $586.0K | — | $-7.1M | — | -1207.2% |
Q1 2024 2024-03-31 | $535.0K | — | $-7.7M | — | -1447.3% |
Q4 2023 2023-12-31 | $709.0K | — | $-8.5M | — | -1196.8% |
Q3 2023 2023-09-30 | $459.0K | — | $-10.2M | — | -2212.2% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Services-Medical Laboratories · SIC 8071
Your notes
Keep private notes on RENXF — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
No insider transactions on file for RENXF in the last 12 months.
Source: SEC Form 4 filings. Backfill runs nightly.
Who owns RENXF
No institutional holdings on file for RENXF yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
Coming once RENXF's latest filing finishes processing.